Compare GFL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFL | NBIX |
|---|---|---|
| Founded | 2007 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 15.5B |
| IPO Year | 2019 | 1996 |
| Metric | GFL | NBIX |
|---|---|---|
| Price | $42.57 | $146.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | $55.22 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 2.4M | 927.8K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $8.18 | $24.73 |
| Revenue Next Year | $7.20 | $13.14 |
| P/E Ratio | ★ $5.95 | $44.30 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $33.33 | $122.14 |
| 52 Week High | $48.07 | $186.12 |
| Indicator | GFL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 31.77 |
| Support Level | $41.08 | $125.85 |
| Resistance Level | $42.26 | $161.41 |
| Average True Range (ATR) | 1.23 | 4.31 |
| MACD | -0.11 | -0.66 |
| Stochastic Oscillator | 29.13 | 6.72 |
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.